The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, ...

There’s a newly approved treatment for multiple myeloma that has returned after earlier therapy. The combination of Tecvayli ...

Revuforj is approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older. The AUGMENT-101 trial showed a 21.2% complete remission rate with a median ...

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James), may offer ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U ...

Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and reduce chemotherapy toxicity. The development of treatments beyond ...

A childhood cancer diagnosis can be unpredictable. What will the treatment be? Will it work? Will my child relapse? Ailani Myers, 9, has relapsed seven times, but her motto remains the same. "We've ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial. The Food and Drug Administration (FDA) ...